PT1119567E
(pt)
|
1998-10-08 |
2005-08-31 |
Astrazeneca Ab |
Derivados de quinazolina
|
UA71945C2
(en)
*
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
PL205557B1
(pl)
|
1999-02-10 |
2010-05-31 |
Astrazeneca Ab |
Pochodne indolu
|
PL354241A1
(en)
*
|
1999-09-17 |
2003-12-29 |
Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg |
Kinase inhibitors as therapeutic agents
|
US7071199B1
(en)
|
1999-09-17 |
2006-07-04 |
Abbott Gmbh & Cco. Kg |
Kinase inhibitors as therapeutic agents
|
MXPA02012870A
(es)
*
|
2000-06-22 |
2003-05-14 |
Pfizer Prod Inc |
Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.
|
WO2002012226A1
(fr)
|
2000-08-09 |
2002-02-14 |
Astrazeneca Ab |
Derives de la quinoline presentant une activite inhibant le facteur de croissance vegf
|
DE60134679D1
(de)
|
2000-10-20 |
2008-08-14 |
Eisai R&D Man Co Ltd |
Stickstoff enthaltende aromatische Heterozyklen
|
DK1370552T3
(da)
*
|
2001-03-23 |
2007-05-07 |
Bayer Pharmaceuticals Corp |
Rho-kinase-inhibitorer
|
CA2441492C
(fr)
*
|
2001-03-23 |
2011-08-09 |
Bayer Corporation |
Inhibiteurs de rho-kinase
|
EP1249451B1
(fr)
*
|
2001-04-13 |
2006-06-21 |
Pfizer Products Inc. |
Dérivés de 4-aminopyridopyrimidine substitués
|
AU2002345792A1
(en)
|
2001-06-21 |
2003-01-08 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
KR20050042055A
(ko)
*
|
2001-11-03 |
2005-05-04 |
아스트라제네카 아베 |
항종양제로서의 퀴나졸린 유도체
|
GB0126433D0
(en)
*
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
HUP0500117A3
(en)
*
|
2001-11-30 |
2008-03-28 |
Pfizer Prod Inc |
Processes for the preparation of substituted quinazoline derivatives for the treatment of abnormal cell growth
|
EP1465632A1
(fr)
*
|
2001-12-12 |
2004-10-13 |
Pfizer Products Inc. |
Derives de quinazoline pour le traitement de croissance cellulaire anormale
|
EP1463507A1
(fr)
*
|
2001-12-19 |
2004-10-06 |
SmithKline Beecham Corporation |
Composes de thienopyrimidine en tant qu'inhibiteurs de la proteine tyrosine kinase
|
US20030143165A1
(en)
*
|
2002-01-25 |
2003-07-31 |
Allan Evans |
NSAID-containing topical formulations that demonstrate chemopreventive activity
|
RU2362774C1
(ru)
|
2002-02-01 |
2009-07-27 |
Астразенека Аб |
Хиназолиновые соединения
|
TW200302722A
(en)
*
|
2002-02-13 |
2003-08-16 |
Astrazeneca Ab |
Therapeutic agents
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
WO2003094830A2
(fr)
*
|
2002-05-07 |
2003-11-20 |
Neurosearch A/S |
Nouveaux derives d'ethynyl azacycliques
|
RU2341296C2
(ru)
*
|
2002-05-24 |
2008-12-20 |
Энджиотек Интернэшнл Аг |
Композиции и способы покрытия медицинских имплантатов
|
US8313760B2
(en)
*
|
2002-05-24 |
2012-11-20 |
Angiotech International Ag |
Compositions and methods for coating medical implants
|
ATE323702T1
(de)
|
2002-08-06 |
2006-05-15 |
Astrazeneca Ab |
Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
|
EP1567506A4
(fr)
|
2002-11-20 |
2007-06-20 |
Array Biopharma Inc |
Cyanoguanidines et cyanoamidines utilisees comme inhibiteurs de erbb2 et egfr
|
US20040186160A1
(en)
*
|
2002-12-13 |
2004-09-23 |
Sugen, Inc. |
Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
|
MXPA05006335A
(es)
*
|
2002-12-18 |
2005-08-26 |
Pfizer Prod Inc |
Derivados biciclicos para el tratamiento del crecimiento celular anormal.
|
JP3814285B2
(ja)
*
|
2002-12-19 |
2006-08-23 |
ファイザー・インク |
眼疾患の治療に有用なプロテインキナーゼ阻害剤としての2−(1h−インダゾール−6−イルアミノ)−ベンズアミド化合物
|
GB0309009D0
(en)
*
|
2003-04-22 |
2003-05-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
BRPI0410720A
(pt)
*
|
2003-05-27 |
2006-06-20 |
Pfizer Prod Inc |
quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
AU2004253967B2
(en)
*
|
2003-07-03 |
2010-02-18 |
Cytovia, Inc. |
4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
|
HN2004000285A
(es)
*
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
WO2005026151A1
(fr)
*
|
2003-09-16 |
2005-03-24 |
Astrazeneca Ab |
Dérivés de quinozaline en tant qu'inhibiteurs de la tyrosine kinase
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
EP1683785B1
(fr)
|
2003-11-11 |
2013-10-16 |
Eisai R&D Management Co., Ltd. |
Derive d'uree et son procede de production
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
US20050158356A1
(en)
*
|
2003-11-20 |
2005-07-21 |
Angiotech International Ag |
Implantable sensors and implantable pumps and anti-scarring agents
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
CN1914182B
(zh)
|
2004-02-03 |
2011-09-07 |
阿斯利康(瑞典)有限公司 |
喹唑啉衍生物
|
BRPI0509580A
(pt)
*
|
2004-03-30 |
2007-11-27 |
Pfizer Prod Inc |
combinações de inibidores de transdução de sinal
|
US20080269238A1
(en)
*
|
2004-04-01 |
2008-10-30 |
Takeda Pharmaceutical Company Limited |
Thiazolopyrimidine Derivative
|
MXPA06013996A
(es)
*
|
2004-06-02 |
2007-02-08 |
Takeda Pharmaceutical |
Compuesto heterociclico fusionado.
|
US20070232607A1
(en)
*
|
2004-06-04 |
2007-10-04 |
Bradbury Robert H |
Quinazoline Derivatives as Erbb Receptor Tyrosine kinases
|
EP1768984B1
(fr)
|
2004-07-16 |
2010-10-20 |
Sunesis Pharmaceuticals, Inc. |
Thienopyrimidines utiles en tant qu'inhibiteurs des kinases aurora
|
CA2575808A1
(fr)
*
|
2004-08-02 |
2006-02-16 |
Osi Pharmaceuticals, Inc. |
Composes a base de pyrrolopyrimidine a substitution arylamine inhibiteurs de kinases multiples
|
PL1786785T3
(pl)
*
|
2004-08-26 |
2010-08-31 |
Pfizer |
Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
|
PT1784396E
(pt)
*
|
2004-08-26 |
2011-01-27 |
Pfizer |
Compostos amino-heteroarílicos substituídos com pirazole como inibidores de proteína quinases
|
WO2006021886A1
(fr)
*
|
2004-08-26 |
2006-03-02 |
Pfizer Inc. |
Composes aminoheteroaryles en tant qu'inhibiteurs des proteines tyrosine kinases
|
ES2322175T3
(es)
|
2004-09-17 |
2009-06-17 |
EISAI R&D MANAGEMENT CO., LTD. |
Composicion medicinal con estabilidad mejorada y gelificacion reducida.
|
US7285569B2
(en)
|
2004-09-24 |
2007-10-23 |
Hoff Hoffmann-La Roche Inc. |
Tricycles, their manufacture and use as pharmaceutical agents
|
AR050948A1
(es)
|
2004-09-24 |
2006-12-06 |
Hoffmann La Roche |
Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer.
|
US20060107555A1
(en)
*
|
2004-11-09 |
2006-05-25 |
Curtis Marc D |
Universal snow plow adapter
|
ATE501148T1
(de)
|
2004-12-14 |
2011-03-15 |
Astrazeneca Ab |
Pyrazolopyrimidinverbindungen als antitumormittel
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
CN101287369A
(zh)
*
|
2005-01-03 |
2008-10-15 |
美瑞德生物工程公司 |
治疗脑癌的方法
|
CA2592900A1
(fr)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics Inc. |
Composes et utilisation therapeutique associee
|
GB0504474D0
(en)
*
|
2005-03-04 |
2005-04-13 |
Astrazeneca Ab |
Chemical compounds
|
EP1863848A4
(fr)
|
2005-03-31 |
2009-09-23 |
Agensys Inc |
Anticorps et molecules correspondantes qui se fixent aux proteines 161p2f10b
|
US7462639B2
(en)
|
2005-04-14 |
2008-12-09 |
Hoffmann-La Roche Inc. |
Aminopyrazole derivatives
|
MX2007013304A
(es)
|
2005-04-26 |
2007-12-13 |
Pfizer |
Anticuerpos de p-caderina.
|
GB0508717D0
(en)
*
|
2005-04-29 |
2005-06-08 |
Astrazeneca Ab |
Chemical compounds
|
GB0508715D0
(en)
*
|
2005-04-29 |
2005-06-08 |
Astrazeneca Ab |
Chemical compounds
|
CA2610655A1
(fr)
|
2005-06-03 |
2006-12-14 |
Abbott Laboratories |
Derives de cyclobutyl amine
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
PL2447283T3
(pl)
|
2005-09-07 |
2015-12-31 |
Amgen Fremont Inc |
Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1 (ALK-1)
|
DE602006018331D1
(de)
*
|
2005-09-20 |
2010-12-30 |
Astrazeneca Ab |
4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
|
ES2374450T3
(es)
|
2005-09-20 |
2012-02-16 |
OSI Pharmaceuticals, LLC |
Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
|
EP1940825A1
(fr)
*
|
2005-09-20 |
2008-07-09 |
Astra Zeneca AB |
Derives de quinazoline utilises comme agents anticancereux
|
US7576110B2
(en)
|
2005-09-22 |
2009-08-18 |
Abbott Laboratories |
Benzothiazole cyclobutyl amine derivatives
|
TW200730527A
(en)
*
|
2005-12-02 |
2007-08-16 |
Takeda Pharmaceuticals Co |
Fused heterocyclic compound
|
JP2009517450A
(ja)
*
|
2005-12-02 |
2009-04-30 |
アストラゼネカ アクチボラグ |
チロシンキナーゼ阻害薬としての4−アニリノ置換キナゾリン誘導体
|
CN101321739A
(zh)
*
|
2005-12-02 |
2008-12-10 |
阿斯利康(瑞典)有限公司 |
用作erbB酪氨酸激酶抑制剂的喹唑啉衍生物
|
US20070129364A1
(en)
*
|
2005-12-07 |
2007-06-07 |
Han-Qing Dong |
Pyrrolopyridine kinase inhibiting compounds
|
US7572809B2
(en)
|
2005-12-19 |
2009-08-11 |
Hoffmann-La Roche Inc. |
Isoquinoline aminopyrazole derivatives
|
EP1971611B1
(fr)
|
2005-12-21 |
2012-10-10 |
Abbott Laboratories |
Composes anti-viraux
|
AU2006330924B2
(en)
|
2005-12-21 |
2012-03-15 |
Abbvie Inc. |
Anti-viral compounds
|
RU2467007C2
(ru)
|
2005-12-21 |
2012-11-20 |
Эбботт Лэборетриз |
Производные [1,8]нафтиридина, полезные в качестве ингибиторов репликации вируса hcv
|
US20070231298A1
(en)
*
|
2006-03-31 |
2007-10-04 |
Cell Genesys, Inc. |
Cytokine-expressing cancer immunotherapy combinations
|
MEP43308A
(en)
|
2006-05-09 |
2011-02-10 |
Pfizer Prod Inc |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
WO2007136103A1
(fr)
|
2006-05-18 |
2007-11-29 |
Eisai R & D Management Co., Ltd. |
Agent antitumoral destiné au cancer de la thyroïde
|
CN103382174A
(zh)
|
2006-06-23 |
2013-11-06 |
雅培制药有限公司 |
作为组胺h3受体调节物的环丙胺衍生物
|
US9108948B2
(en)
|
2006-06-23 |
2015-08-18 |
Abbvie Inc. |
Cyclopropyl amine derivatives
|
WO2008026748A1
(fr)
|
2006-08-28 |
2008-03-06 |
Eisai R & D Management Co., Ltd. |
Agent antitumoral pour cancer gastrique non différencié
|
EP1921070A1
(fr)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
heterocycles bicycliques, medicaments á base de ces composes, leur usage et procédé pour leur preparation
|
RU2009126576A
(ru)
*
|
2006-12-12 |
2011-01-20 |
Такеда Фармасьютикал Компани Лимитед (Jp) |
Конденсированное гетероциклическое соединение
|
TWI399380B
(zh)
|
2006-12-20 |
2013-06-21 |
Abbott Lab |
抗病毒化合物
|
KR101445892B1
(ko)
|
2007-01-29 |
2014-09-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암 치료용 조성물
|
KR100799821B1
(ko)
*
|
2007-02-05 |
2008-01-31 |
동화약품공업주식회사 |
신규한 이마티닙 캠실레이트 및 그의 제조방법
|
WO2008095847A1
(fr)
|
2007-02-06 |
2008-08-14 |
Boehringer Ingelheim International Gmbh |
Hétérocycles bicycliques, agents pharmaceutiques contenant ces composés, leur utilisation et leur procédé de préparation
|
EP2076289B1
(fr)
|
2007-04-13 |
2014-11-12 |
Dana-Farber Cancer Institute, Inc. |
Méthodes de traitement d'un cancer résistant à des agents thérapeutiques anti-erbb
|
EP2137535B1
(fr)
*
|
2007-04-13 |
2015-06-03 |
Dana-Farber Cancer Institute, Inc. |
Établissement du profil de récepteurs tyrosine kinases
|
US7956190B2
(en)
|
2007-06-25 |
2011-06-07 |
Hoffmann-La Roche Inc. |
Benzimidazole amido derivatives as kinase inhibitors
|
CA2698287A1
(fr)
|
2007-09-07 |
2009-03-12 |
Agensys, Inc. |
Anticorps et molecules apparentees qui se lient aux proteines 24p4c12
|
US8952035B2
(en)
|
2007-11-09 |
2015-02-10 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
EP2245026B1
(fr)
|
2008-02-07 |
2012-08-01 |
Boehringer Ingelheim International GmbH |
Hétérocycles spirocycliques, médicaments contenant ces composés, leur utilisation et procédé pour les produire
|
PE20091580A1
(es)
*
|
2008-03-12 |
2009-11-05 |
Takeda Pharmaceutical |
Compuesto heterociclico fusionado
|
US7932036B1
(en)
|
2008-03-12 |
2011-04-26 |
Veridex, Llc |
Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
|
JP5739802B2
(ja)
|
2008-05-13 |
2015-06-24 |
アストラゼネカ アクチボラグ |
4−(3−クロロ−2−フルオロアニリノ)−7−メトキシ−6−{[1−(n−メチルカルバモイルメチル)ピペリジン−4−イル]オキシ}キナゾリンのフマル酸塩
|
AU2009263037B2
(en)
*
|
2008-06-26 |
2011-10-06 |
Amgen Inc. |
Alkynyl alcohols as kinase inhibitors
|
US20100029675A1
(en)
*
|
2008-07-25 |
2010-02-04 |
Hwang Soo-In |
Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use
|
EP2313397B1
(fr)
|
2008-08-08 |
2016-04-20 |
Boehringer Ingelheim International GmbH |
Hétérocycles substitués par cyclohexyloxy, médicament contenant ces liaisons, leur utilisation et leur procédé de fabrication
|
AR073501A1
(es)
|
2008-09-08 |
2010-11-10 |
Boehringer Ingelheim Int |
Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa
|
EP2241565A1
(fr)
|
2009-01-15 |
2010-10-20 |
Universität Leipzig |
Composés inhibiteurs de l'aurora kinase
|
CN102307875A
(zh)
*
|
2009-02-09 |
2012-01-04 |
苏伯俭股份有限公司 |
吡咯并嘧啶基axl激酶抑制剂
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
EP2400990A2
(fr)
|
2009-02-26 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Procédés in situ pour surveiller l'état emt de cellules tumorales in vivo
|
WO2010099138A2
(fr)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
|
JP2012519281A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
WO2010098866A1
(fr)
|
2009-02-27 |
2010-09-02 |
Supergen, Inc. |
Inhibiteurs cyclopentathiophène/cyclohexathiophène de l'adn méthyltransférase
|
JP2012519282A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
US9186353B2
(en)
|
2009-04-27 |
2015-11-17 |
Abbvie Inc. |
Treatment of osteoarthritis pain
|
EP2473500A2
(fr)
|
2009-09-01 |
2012-07-11 |
Pfizer Inc. |
Dérivés de benzimidazole
|
US20110275644A1
(en)
|
2010-03-03 |
2011-11-10 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
EP2542893A2
(fr)
|
2010-03-03 |
2013-01-09 |
OSI Pharmaceuticals, LLC |
Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1
|
BR112012032462A2
(pt)
|
2010-06-25 |
2016-11-08 |
Eisai R&D Man Co Ltd |
agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
|
CN106244707A
(zh)
|
2010-07-28 |
2016-12-21 |
维里德克斯有限责任公司 |
急性髓细胞性白血病应答法尼基转移酶抑制剂治疗的测定方法
|
WO2012037258A1
(fr)
|
2010-09-16 |
2012-03-22 |
Abbott Laboratories |
Procédés de préparation de dérivés cyclopropyliques substitués en 1,2
|
ES2543151T3
(es)
|
2010-10-20 |
2015-08-17 |
Pfizer Inc |
Derivados de 2-piridina como moduladores del receptor Smoothened
|
US9409900B2
(en)
*
|
2010-11-09 |
2016-08-09 |
Fujian Haixi Pharmaceuticals, Inc. |
Compound for increasing kinase active and application thereof
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
US8962650B2
(en)
|
2011-04-18 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
US20140178368A1
(en)
|
2011-04-19 |
2014-06-26 |
Leslie Lynne SHARP |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
EP3444363B1
(fr)
|
2011-06-03 |
2020-11-25 |
Eisai R&D Management Co., Ltd. |
Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib
|
EP3409278B8
(fr)
|
2011-07-21 |
2020-11-04 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Inhibiteurs de protéine kinase hétérocycliques
|
CA2847540C
(fr)
|
2011-09-22 |
2016-05-17 |
Pfizer Inc. |
Derives de pyrrolopyrimidine et de purine
|
CA2856149A1
(fr)
|
2011-11-08 |
2013-05-16 |
Pfizer Inc. |
Procedes de traitement de troubles inflammatoires utilisant des anticorps anti-m-csf
|
TWI577671B
(zh)
*
|
2011-11-14 |
2017-04-11 |
Sunshine Lake Pharma Co Ltd |
Aminoquinazoline derivatives and salts thereof and methods of use thereof
|
WO2013152252A1
(fr)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Polythérapie antinéoplasique
|
ES2644758T3
(es)
|
2012-10-16 |
2017-11-30 |
Tolero Pharmaceuticals, Inc. |
Moduladores de PKM2 y métodos para su uso
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
MX2015004979A
(es)
|
2012-12-21 |
2015-07-17 |
Eisai R&D Man Co Ltd |
Forma amorfa de derivado de quinolina y metodo para su produccion.
|
US9468681B2
(en)
|
2013-03-01 |
2016-10-18 |
California Institute Of Technology |
Targeted nanoparticles
|
CN105308033B
(zh)
|
2013-03-14 |
2018-08-24 |
特雷罗药物股份有限公司 |
Jak2和alk2抑制剂及其使用方法
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
ES2687968T3
(es)
|
2013-05-14 |
2018-10-30 |
Eisai R&D Management Co., Ltd. |
Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
CN103784412A
(zh)
*
|
2014-01-15 |
2014-05-14 |
青岛市肿瘤医院 |
一种盐酸埃克替尼分散片及其制备方法
|
WO2015155624A1
(fr)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dérivés de dihydropyrrolopyrimidine
|
JP6574203B2
(ja)
|
2014-04-30 |
2019-09-11 |
ファイザー・インク |
シクロアルキル結合ジヘテロ環誘導体
|
WO2016001789A1
(fr)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Dérivés de pyrimidine en tant qu'inhibiteurs de pi3k destinés à être utilisés dans le traitement du cancer
|
BR112017002827B1
(pt)
|
2014-08-28 |
2023-04-18 |
Eisai R&D Management Co., Ltd |
Derivado de quinolina altamente puro e método para produção do mesmo
|
MX2017010474A
(es)
|
2015-02-25 |
2017-11-28 |
Eisai R&D Man Co Ltd |
Metodo para suprimir el amargor de un derivado de quinoleina.
|
KR20240064733A
(ko)
|
2015-03-04 |
2024-05-13 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
MX2017013383A
(es)
|
2015-04-20 |
2017-12-07 |
Tolero Pharmaceuticals Inc |
Prediccion de respuesta a alvocidib mediante perfilado mitocondrial.
|
TR201911032T4
(tr)
|
2015-05-18 |
2019-08-21 |
Tolero Pharmaceuticals Inc |
Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları.
|
SG11201710198YA
(en)
|
2015-06-16 |
2018-01-30 |
Eisai R&D Man Co Ltd |
Anticancer agent
|
CN111643479B
(zh)
|
2015-07-01 |
2023-10-27 |
加州理工学院 |
基于阳离子粘酸聚合物的递送系统
|
WO2017009751A1
(fr)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Dérivés de pyrimidine
|
AU2016301315C1
(en)
|
2015-08-03 |
2022-07-07 |
Sumitomo Pharma Oncology, Inc. |
Combination therapies for treatment of cancer
|
EP3383375A1
(fr)
|
2015-12-03 |
2018-10-10 |
Agios Pharmaceuticals, Inc. |
Inhibiteurs de mat2a pour le traitement du cancer n'exprimant pas mtap
|
WO2018094275A1
(fr)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Promédicaments de l'alvocidib et leur utilisation en tant qu'inhibiteurs de protéines kinases
|
KR20190099260A
(ko)
|
2016-12-19 |
2019-08-26 |
톨레로 파마수티컬스, 인크. |
프로파일링 펩티드 및 감도 프로파일링을 위한 방법
|
WO2019055579A1
(fr)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
Régime de traitement pour des cancers qui sont insensibles aux inhibiteurs de bcl-2 à l'aide de l'inhibiteur de mcl-1 alvocidib
|
KR102616949B1
(ko)
|
2017-09-14 |
2023-12-22 |
다이이찌 산쿄 가부시키가이샤 |
고리형 구조를 갖는 화합물
|
WO2019075367A1
(fr)
|
2017-10-13 |
2019-04-18 |
Tolero Pharmaceuticals, Inc. |
Activateurs de pkm2 en combinaison avec des espèces réactives de l'oxygène pour le traitement du cancer
|
JOP20180094A1
(ar)
|
2017-10-18 |
2019-04-18 |
Hk Inno N Corp |
مركب حلقي غير متجانس كمثبط بروتين كيناز
|
US11708335B2
(en)
|
2017-12-18 |
2023-07-25 |
Sterngreene, Inc. |
Pyrimidine compounds useful as tyrosine kinase inhibitors
|
WO2019241327A1
(fr)
|
2018-06-13 |
2019-12-19 |
California Institute Of Technology |
Nanoparticules permettant de traverser la barrière hématoencéphalique et méthodes de traitement faisant appel à celle-ci
|
CN112512597A
(zh)
|
2018-07-26 |
2021-03-16 |
大日本住友制药肿瘤公司 |
用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
|
EP3856726A1
(fr)
|
2018-09-25 |
2021-08-04 |
Black Diamond Therapeutics, Inc. |
Dérivés de quinazoline utilisés en tant qu'inhibiteur de tyrosine kinase, compositions, leurs procédés de préparation et leur utilisation
|
WO2020117988A1
(fr)
|
2018-12-04 |
2020-06-11 |
Tolero Pharmaceuticals, Inc. |
Inhibiteurs de cdk9 et leurs polymorphes destinés à être utilisés en tant qu'agents pour le traitement du cancer
|
CA3127502A1
(fr)
|
2019-02-12 |
2020-08-20 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Formulations comprenant des inhibiteurs de proteine kinase heterocycliques
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
EP3941463A1
(fr)
|
2019-03-22 |
2022-01-26 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprenant des modulateurs de pkm2 et méthodes de traitement les utilisant
|
WO2021155006A1
(fr)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations
|
WO2021179274A1
(fr)
*
|
2020-03-13 |
2021-09-16 |
Suzhou Zanrong Pharma Ltd. |
Inhibiteurs de récepteurs erbb utilisés comme agents antitumoraux
|
KR102234530B1
(ko)
*
|
2020-09-01 |
2021-03-31 |
대한민국 |
신규 톨트라주릴 유도체 및 이를 포함하는 쿠도아충 예방·치료를 위한 약학 조성물
|
WO2022221227A1
(fr)
|
2021-04-13 |
2022-10-20 |
Nuvalent, Inc. |
Hétérocycles amino-substitués pour le traitement de cancers avec des mutations egfr
|